U.S. Stock News

Corvus Pharmaceuticals (CRVS) has drawn investor attention after appointing immunologist and drug development leader Dr. Andrew C. Chan to its Board of Directors. The move highlights the company’s focus on research driven decision making. See our latest analysis for Corvus Pharmaceuticals. The latest share price of US$15.46 comes after a mixed few months, with a 7.1% 30 day share price return set against a 25.3% decline over 90 days. At the same time, a year to date share price return of...

If you are wondering whether Group 1 Automotive at around US$353.67 is a bargain or fully priced, the key is to understand what the current share price implies about the company’s value. The stock has moved 3.6% over the last week and 6.9% over the last month. Year to date it shows a 9.9% decline and a 13.8% decline over the past year, set against longer term returns of 63.3% over three years and 115.7% over five years. Recent coverage of Group 1 Automotive has focused on the company’s...

Wondering if Penumbra at around US$325.33 is offering you real value or just a rich price tag? This article walks through what the latest numbers actually say about the stock. The share price shows a 1.4% decline over the last 7 days and a 1.1% decline over the last 30 days, while returns stand at 5.1% year to date and 9.9% over the past year. Recent coverage around Penumbra has focused on its position in the medical equipment space and how investors are weighing growth potential against...

Artisan Partners Asset Management (NYSE:APAM) is signaling a push into acquisitions and new investment strategies in differentiated credit, private equity and real assets. Management has highlighted an active M&A pipeline, interest in both individual hires and larger deals, and continued R&D efforts to expand the firm’s platform. The company plans to pursue these opportunities while keeping significant excess capital available for potential transactions and organic growth...

Ensign Group (ENSG) just posted Q1 2026 results with revenue of US$1.4 billion, basic EPS of US$1.73 and net income of US$99.7 million, setting the tone for the new fiscal year. Over the past five quarters, revenue has moved from US$1.17 billion in Q1 2025 to US$1.39 billion in Q1 2026, while quarterly basic EPS has increased from US$1.41 to US$1.73, with trailing twelve month net income at US$363.4 million. With net profit margins over the last year near 7%, the focus now is on how...

For readers wondering whether Provident Financial Services at around US$22.38 is still offering value or if most of the opportunity is already priced in, this article walks through what the current numbers suggest. The stock has recent returns of 0.1% over 7 days, 5.2% over 30 days, 13.3% year to date, 37.6% over 1 year, 67.1% over 3 years and 13.2% over 5 years. These figures naturally raise questions about how much upside or downside might be left. Recent news flow around Provident...

In April 2026, Matson, Inc.’s Board declared a past second-quarter dividend of US$0.36 per share, payable on June 4, 2026 to shareholders of record on May 7, 2026. On the same day, Matson also expanded and extended its share repurchase authorization to 18,000,000 shares through December 31, 2029, highlighting ongoing cash returns to shareholders. We’ll now examine how Matson’s expanded share repurchase authorization could influence the company’s existing investment narrative and future...

Event context and recent share performance Equity LifeStyle Properties (ELS) has recently drawn investor attention after a mild share pullback, with the stock closing at $62.82 and showing small negative returns over the week, month and past 3 months. See our latest analysis for Equity LifeStyle Properties. That recent pullback sits against a quieter backdrop, with a 5.07% year to date share price return but a 1.05% decline in 1 year total shareholder return hinting that momentum has...

Essex Property Trust overview after recent performance Essex Property Trust (ESS) has drawn fresh attention after recent price moves, with the stock last closing at US$263.35 and showing mixed total returns across the past year and past 3 months. See our latest analysis for Essex Property Trust. The share price has picked up recently, with a 1 month share price return of 8.34% and a 3 month share price return of 4.56%. However, the 1 year total shareholder return of 6.45% contrasts with a 3...

D.R. Horton (NYSE:DHI) has launched its first new home community in Rochester, Minnesota. The move marks the company’s entry into the Rochester housing market. This expansion adds a new Upper Midwest city to D.R. Horton's existing geographic footprint. D.R. Horton, a large U.S. homebuilder, focuses on building and selling new homes across a range of price points. By entering Rochester, Minnesota, NYSE:DHI is extending its presence into a new metro area in the Upper Midwest, a region that...

If you are wondering whether Zions Bancorporation National Association is priced attractively right now, it helps to start with what the recent share performance and valuation checks are signaling. The stock last closed at US$63.26, with returns of 3.1% over 7 days, 8.6% over 30 days, 6.8% year to date, 40.3% over 1 year and 199.5% over 3 years, while the 5 year return stands at 26.7%. Recent headlines around US banks, including Zions Bancorporation National Association, have focused on...

Investors may be wondering whether Highwoods Properties at around US$24.71 is starting to look like value, or if the price still does not quite stack up. The stock has recently shown mixed returns, with a 3.4% gain over 7 days and 15.4% over 30 days, set against a 4.5% decline year to date and an 8.9% decline over the past year. Recent coverage has focused on how office focused real estate investment trusts fit into investors' portfolios as hybrid work patterns and demand for office space...

Crane Company (NYSE:CR) reported a strong Q1 2026, with net sales supported by the integration of several recent acquisitions. Management raised full year 2026 guidance and outlined plans for further M&A, citing a solid acquisition pipeline and balance sheet. The company is targeting significant total sales growth for 2026, with recent deals already contributing earlier than initially expected. Crane Company, traded as NYSE:CR, operates as a diversified industrial business, supplying...

Viatris (NasdaqGS:VTRS) is presenting pivotal Phase 3 results for its investigational low dose estrogen contraceptive weekly patch at a major scientific meeting. The U.S. FDA has accepted the New Drug Application for the patch and set a target action date in July 2026. The product is positioned within Viatris' women's health franchise and represents a potential new entrant in the contraceptive market. For investors tracking NasdaqGS:VTRS, this contraceptive patch sits within a broader...

If you are wondering whether HealthEquity at around US$82.40 is a bargain or already pricing in a lot of optimism, it helps to break the story down into what the market has been doing and what the numbers actually say about value. The share price is near US$82.40 after a 0.1% slip over the last week, a 1.2% decline over the last month, and a 9.5% decline year to date, even though the 3 year return sits at 50.5% and the 5 year return at 10.6%. Recent headlines around HealthEquity have kept...

Public Storage recently reported past first-quarter 2026 results, with revenue rising to US$1,217.74 million and net income to US$526.27 million, alongside higher earnings per share and reaffirmed full-year guidance. Management also emphasized early benefits from the PS 4.0 operational upgrade and the ongoing integration of National Storage Affiliates, which they expect to enhance efficiency and long-term earnings power. Next, we’ll examine how the reaffirmed 2026 guidance and PS 4.0...

Axogen stock moves after recent performance data Axogen (AXGN) has drawn fresh attention after recent performance data showed a 28.89% move over the past month and a 24.19% gain over the past 3 months, prompting closer scrutiny of its valuation and fundamentals. See our latest analysis for Axogen. That shorter term strength sits on top of a longer run picture, where the year to date share price return of 39.61% supports a very large 1 year total shareholder return of 152.66% and a 3 year...

Illumina (ILMN) opened 2026 with Q1 revenue of US$1,091 million and basic EPS of US$0.88, setting the tone for how the year is starting to shape up after its recent return to profitability. Over the past five quarters, revenue has moved within a tight band between US$1,041 million and US$1,159 million, while quarterly basic EPS has ranged from US$0.82 to US$2.18. This gives investors a clearer view of how earnings power has translated from the top line. With trailing 12 month net income back...

Without a specific news headline driving Hancock Whitney (HWC) today, the stock still draws attention from investors who are reviewing recent returns, profitability figures, and its current share price of US$67.17. See our latest analysis for Hancock Whitney. Recent trading has been relatively steady, with a 1 month share price return of 4.77% and a year to date share price return of 4.20%, set against a 1 year total shareholder return of 28.01% that builds on a 109.91% total shareholder...

Roku (ROKU) has just opened 2026 earnings season with Q1 results that build on a clear turnaround in the numbers, capped by Q4 2025 revenue of about US$1.4b and basic EPS of US$0.54. Over the past year, quarterly revenue has moved from US$1,201.0m in Q4 2024 to US$1,394.9m in Q4 2025, while basic EPS shifted from a loss of US$0.24 to a profit of US$0.54. This sets up a story in which improving profitability sits at the center of the earnings debate, with margins in focus as investors weigh...

If you are wondering whether Cognizant Technology Solutions is attractively priced right now, the key is understanding what the current share price implies about its future. The stock last closed at US$52.43, after returns of a 4.9% decline over 7 days, 14.4% decline over 30 days, 35.5% decline year to date, 31.3% decline over 1 year, 12.9% decline over 3 years, and 24.1% decline over 5 years. Recent share price moves sit against a broader backdrop of ongoing interest in large IT services...

For investors considering whether Guardant Health at around US$87.60 represents fair value or a potential opportunity, this article examines what that price may indicate about the stock. The share price is US$87.60 after a 1.5% decline over the past week and a 3.9% decline over the past month. It is still up 87.0% over the past year and 270.4% over three years, while a 35.3% decline over five years provides additional context. Recent news about Guardant Health has highlighted its role in...

IDEAYA Biosciences (IDYA) is back in focus after the FDA agreed to review its New Drug Application for darovasertib plus crizotinib in first line metastatic uveal melanoma under a Real-Time Oncology Review program. See our latest analysis for IDEAYA Biosciences. Even with the FDA review decision and recent positive Phase 2/3 data, IDEAYA Biosciences’ share price has pulled back, with a 30 day share price return of a 13.21% decline and a year to date share price return of a 16.72% decline,...

Wondering whether Sportradar Group's current share price reflects its true worth, or if the market is mispricing the story. The stock last closed at US$13.26, with returns of 0.2% over 7 days, a 20.3% decline over 30 days, and year to date and 1 year returns of 43.1% and 44.1% declines, while the 3 year return sits at 1.8%. Recent coverage has focused on Sportradar Group as a listed sports data and technology provider, with attention on how it is positioned in the wider sports betting and...